HR and breast carcinoma: The safety profile of ribociclib was consistent with that of other subgroups (Conte P et al. First-line ribociclib + letrozole in patients with HR+/HER2– advanced breast cancer who received prior (neo)adjuvant therapy: a subgroup analysis of the MONALEESA-2 trial.